VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Zafar on the Potential of Immunotherapy in Colorectal Cancer

S. Yousuf Zafar, MD
Published: Monday, Aug 31, 2015



S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Recent data have shown that PD-1 inhibitors demonstrated activity in patients with mismatch repair-deficient metastatic CRC. These patients experienced a durable and significant response rate, Zafar adds. In terms of standard practice going forward, he questions how practitioners will incorporate immunotherapy into practice, if at all.

Zafar hopes that similar data from larger studies will be just as promising. However, practitioners should be reserved in integrating these therapies into patients’ treatment plans until stronger evidence exists.



S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Recent data have shown that PD-1 inhibitors demonstrated activity in patients with mismatch repair-deficient metastatic CRC. These patients experienced a durable and significant response rate, Zafar adds. In terms of standard practice going forward, he questions how practitioners will incorporate immunotherapy into practice, if at all.

Zafar hopes that similar data from larger studies will be just as promising. However, practitioners should be reserved in integrating these therapies into patients’ treatment plans until stronger evidence exists.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x